An observational study in Cognitive Impairment and Dementia, sponsored by Massachusetts General Hospital. Active, not recruiting at 17 sites in United States. Open to participants aged 60 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-29.
Sponsored by Massachusetts General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Cognitive Dysfunction by Massachusetts General Hospital — 14 open to participants now, 16 under way, none of them phase 3. Cognitive Dysfunction · Massachusetts General Hospital.
Among the 33 studies in Cognitive Dysfunction by Massachusetts General Hospital, this one is one of 3 that started in 2021, is one of 6 observational ones, reaches primary completion later than 7 of the 15 other live ones, and was the 24th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →14 of the 33 studies in Cognitive Dysfunction by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 55+
Massachusetts General Hospital · Sites in United States
Ages 40–99 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 50–80 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 25–50
Massachusetts General Hospital · Sites in United States
Ages 50+
By country, each count listing its studies:
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 60 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 4 2
First in 2005; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,892 is above the median of 150 across 1,000 observational studies indexed under Cognitive Dysfunction.
Median enrollment 40 across the 27 interventional studies, 226 across the 6 observational. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
10 of the studies in Cognitive Dysfunction by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05857137Massachusetts General HospitalPsychosis TMS Study | 2026-11-30 |
| NCT05881239Massachusetts General HospitalDigital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD | 2026-12-30 |
| NCT06538311Massachusetts General HospitalTranscranial Magnetic Stimulation Treatment for Alzheimer's Disease | 2027-03-31 |
| NCT07236190Massachusetts General HospitalBiomarker-based Trial of NPC-1 for Alzheimer's Pathology | 2027-06 |
| NCT05904132Massachusetts General HospitalIndividual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease | 2027-06 |
Add all 10 to your calendar (.ics) → With an account.
Among the 33 studies in Cognitive Dysfunction by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) is an NIH-funded consortium dedicated to finding biomarkers involved in age-related thinking and memory problems. Alzheimer's disease and other dementias leave signatures on brain scans or in the blood called biomarkers. The MarkVCID study will measure a panel of candidate biomarkers in 1800 participants and watch them closely to see what they tell us about changes in brain function and risk of memory loss.
Age-related problems in thinking and memory represent some of the greatest risks to public health in the US and globally. Diseases that affect small blood vessels in the brain have been shown to be major contributors to these changes. However, research and patient care can be held back by limited biomarkers that identify who should be treated.
The MarkVCID Consortium includes 17 US medical centers, a Coordinating Center, an External Advisory Committee, and NIH leadership. Data and biospecimens collected as part of this research study will be stored in a research database and biorepositories, so that researchers can use this information to study brain function.
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) is an NIH-funded multisite consortium dedicated to developing promising predictive, diagnostic, target engagement and progression candidate biomarkers of small vessel disease in VCID. MarkVCID is a collaborative consortium of nine North American research sites (consisting of 17 institutions nationwide), a Coordinating Center, External Advisory Committee, and NIH leadership.
MGH serves as the Consortium's Coordinating Center and is comprised of an administrative and data core providing participating research sites with a common support infrastructure that facilitates cross-site collaborations, oversees development of standard operating procedures and data collection methods and manages consortium-wide data.
In phase two of the MarkVCID study, research sites are charged with enrolling and following ≥200 diverse human subjects with cognitive complaints and/or early symptomatic stages of cognitive impairment and dementia potentially associated with cerebrovascular small vessel disease. Sites will share data with the Coordinating Center which will be used for validation studies of chosen consortium biomarkers. Throughout the duration of the study, sites will utilize harmonized procedures and data collection methods to engage in multi-site biomarker validation. Both Cores comply with regulations for the protection of human research subjects (including Good Clinical Practices (GCP), 21 Code of Federal Regulations (CFR)) and with the International Conference on Harmonization (ICH) Regulations E2A and E6.
The study population will be selected from a variety of sources across the MarkVCID Consortium sites. These sources include, but are not limited to:
Clinics:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
No confounding neurologic, psychiatric, or medical disease
*Participants with normal cognition must meet at least one criterion (diabetes, OR hypertension plus, OR MRI factors) for vascular risk prior to enrollment:
Diabetes (at least one of the following):
Hypertension plus (at least two of the following):
MRI factors (at least one of the following):
Exclusion Criteria:
Neurologic Disease: Based on the available data and investigator's impression, exclude those with confounding neurologic disease that would interfere with test performance or with biomarker analysis:
Other neurologic conditions that interfere with test performance or biomarker analysis
Medical and Psychiatric Conditions: Exclude those with medical and psychiatric conditions that would confound the course or interfere with test performance:
to MRI procedures, such as:
Contraindications to CVR:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NC is defined as: 1. No diagnosis of SCD, MCI, or dementia; AND 2. CDR: Sum of Boxes = 0 AND neuropsychological testing in normal range. Participants must have at least 1 of the following criteria prior to enrollment: Diabetes (at least 1): * Fasting (8-hour) blood sugar ≥126 mg/dL * Random or Post-prandial blood sugar ≥200 mg/dL * HbA1C ≥6.5% * Treatment with anti-diabetic medicine Hypertension plus (at least 2): * Use of anti-hypertensive medications for lowering blood pressure for ≥10 years * Current use of 2 or more anti-hypertensive meds for lowering blood pressure * Blood pressure in a research or clinical setting in the last 2 years with SBP ≥140 or DBP ≥90 * Second blood pressure reading in a research or clinical setting in the last 2 years (different date) with SBP ≥140 or DBP ≥90 * Evidence of likely HTN end organ damage MRI factors (at least 1): * Peri-Ventricular Fazekas Extent Grade or Deep Fazekas Extent Grade ≥2 * ≥1 microbleeds * ≥1 lacunar infarcts
Other: No interventions
Subjective cognitive decline is defined as: 1. Cognitive concerns based on a Short eCog-12 score ≥ 3 (based on administration to participant), AND 2. Normal cognition (neuropsychological testing within normal range).
Other: No interventions
Mild cognitive impairment is defined as: 1. There is a cognitive concern, i.e., the subject, the co-participant, or a clinician is concerned about a change in cognition compared to the subject's previous level. 2. There is impairment in one or more cognitive domains (memory, language, executive function, attention, and visuospatial skills) that is greater than would be expected for the patient's age and educational background. 3. There is largely preserved independence in functional abilities (no change from prior level of functioning or requires only extra effort and minimal aids or assistance). 4. There is no evidence of dementia (cognitive changes are mild and there is no evidence of a significant impairment in social or occupational functioning).
Other: No interventions
Mild dementia is defined as: 1. The subject has cognitive or behavioral (neuropsychiatric) symptoms that meet all of the following criteria: 1. Interfere with ability to function as before at work or at usual activities? 2. Represent a decline from previous levels of functioning? 3. Are not explained by delirium or major psychiatric disorder? AND 2. Impairment in one\* or more of the following domains. 1. Impaired ability to acquire and remember new information. 2. Impaired reasoning and handling of complex tasks, poor judgment. 3. Impaired visuospatial abilities. 4. Impaired language functions. 5. Changes in personality, behavior, or comportment \* In the event of single-domain impairment (e.g., language in PPA, behavior in bvFTD, posterior cortical atrophy), the subject must not fulfill criteria for MCI. AND 3. CDR: Global Score = 0.5 or 1
Other: No interventions
This is an observational study with no interventions.
SVD progression as measured by decline in global cognition
Global cognition scores will be calculated at each study timepoint as an average of age- and education-specific z-scores, based on tests scores from the MarkVCID2 cognitive battery (MoCA, Neuropsychological Testing Battery, Clinical Dementia Rating), which is based on Version 3 of the National Alzheimer's Coordinating Center's (NACC) Uniform Data Set (UDS) (Besser 2018).
Time frame: The cognitive battery is implemented, and global cognition calculated, at Baseline and Years 1, 2 and 3 post-baseline.
SVD progression as measured by decline in executive function
The measure of executive function is the Uniform Data Set (v3.0) executive function composite score (UDS3-EF) developed by Staffaroni et al (2021). The UDS3-EF is calculated from the following tests: Category Fluency - Animals; Verbal Fluency - Phonemic Tests (words beginning with F); Number Span Test (Backward); and Trail Making Tests A and B.
Time frame: The cognitive battery is implemented, and executive function calculated, at Baseline and Years 1, 2 and 3 post-baseline.
Plan to share: Yes — MarkVCID research openly shares both within and outside the MarkVCID Consortium to the greatest extent practical. As per the MarkVCID Consortium's Charter, MarkVCID investigators are granted broad access to MarkVCID data, samples, analytic tools, and other resources with relevant permissions in place. MarkVCID data and samples may also be shared with external collaborators in compliance with the Consortium's external data sharing policies outlined in the MarkVCID Data Use Agreement. The process for requesting data and biosamples is described below.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Internal All MarkVCID research sites sign a Consortium Research Agreement governing the sharing of data and biosamples. Data entered in MarkVCID data systems by the research sites becomes available to all MarkVCID members, in accordance with the MarkVCID Data Sharing, Analysis, and Publications Policy and the MarkVCID Research Agreement. External If the request is approved by the MarkVCID Steering Committee, external users sign the DUA to gain access to the data. If biosamples are requested, external users will execute a Material Transfer Agreement (MTA) with the institution(s) providing samples. Biosamples typically ship within 3 months. Electronic data stored by the MarkVCID Consortium repository becomes available to the investigator about 3 weeks after project approval and signing of the DUA. Investigators requesting access to data and biosamples not held by the MarkVCID repository must contact relevant institution(s) and are subject to longer wait times.
Access criteria: A MarkVCID Project Proposal Form must be submitted for data and biosample requests. The form requires an overview, a description of requested data and/or biosamples, assays, experiments to be conducted, and publication plans. Data requests will be reviewed by the Sharing Subcommittee and biosample requests by the Fluid-Based Biomarkers Subcommittee. Reviews will be based on scientific rationale, overlap with already approved analyses, and, for biosample requests, the scientific priority of the study relative to the number of available biosamples. The Steering Committee will then review proposal recommendations and determine approval. Investigators with approved proposals will sign a DUA and receive applicable data via Globus encrypted transfer. Investigators with approved biosample requests will execute necessary MTAs and receive deidentified biosamples from holding sites. Internal requests related to primary hypotheses of prespecified biomarker kits are exempt from the above.
Started Sep 2021 (actual). Primary completion is estimated for Jul 2027, 70 months after the start.
Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 70 months is above that.
Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →